| Literature DB >> 33479659 |
Jeanne Fichez1, Cathia Soulie2, Laurent Le Corre1, Sophie Sayon2, Stéphane Priet3,4, Karine Alvarez3, Olivier Delelis5, Patrick Gizzi6, Guillaume Prestat1, Christine Gravier-Pelletier1, Anne-Geneviève Marcelin2, Vincent Calvez2, Patricia Busca1.
Abstract
Inspired by the antiviral activity of known pyrazole-based HIV inhibitors, we screened our in-house library of pyrazole-based compounds to evaluate their in cellulo activity against HIV-1 replication. Two hits with very similar structures appeared from single and multiple-round infection assays to be non-toxic and active in a dose-dependent manner. Chemical expansion of their series allowed an in-depth and consistent structure-activity-relationship study (SAR) to be built. Further ADME evaluation led to the selection of 4-amino-3-cyano-1-(2-benzyloxyphenyl)-1H-pyrazole-5-carboxylate with an advantageous pharmacokinetic profile. Finally, examination of its mode of action revealed that this compound does not belong to the three main classes of anti-HIV drugs, a feature of prime interest in the context of viral resistance. This journal is © The Royal Society of Chemistry 2020.Entities:
Year: 2020 PMID: 33479659 PMCID: PMC7593888 DOI: 10.1039/d0md00025f
Source DB: PubMed Journal: RSC Med Chem ISSN: 2632-8682